Physician Capacity to Treat Opioid Use Disorder with Buprenorphine-Assisted Treatment
ResearchPosted on rand.org Sep 28, 2016Published in: JAMA, v. 316, no. 11, Sep. 2016, p. 1211-1212
Many physicians who prescribe buprenorphine are prescribing below the patient limits historically allowed under U.S. law.
ResearchPosted on rand.org Sep 28, 2016Published in: JAMA, v. 316, no. 11, Sep. 2016, p. 1211-1212
Buprenorphine, a medication effective in treating individuals with opioid use disorders, can be prescribed in the United States by addiction specialists or by physicians who complete an 8-hour course and obtain a US Drug Enforcement Administration waiver. Waivered prescribers have been restricted to treating up to 30 patients with an opioid use disorder concurrently; after a year, physicians could request that the limit be increased to 100 patients. Policy makers have prioritized increasing capacity to provide buprenorphine to fight the opioid epidemic but lack adequate information about how to do so effectively. Patient censuses of buprenorphine prescribers were examined to provide information on whether patient limits have been a barrier to buprenorphine treatment.
This publication is part of the RAND external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.